6496.TWO Excelsior Biopharma

Healthcare Pharmaceuticals Taiwan OTC Exchange
23.05 TWD
Close of Nov 6, 2026
22.10 30.55
Market cap
TWD 1.07B
P/E
-
P/B
1.56x
ROE
-32.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 6496.TWO undervalued?

Graham number

The Graham number of Excelsior Biopharma cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Excelsior Biopharma fundamental analysis

No fundamental analysis for Excelsior Biopharma yet.

Excelsior Biopharma stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Excelsior Biopharma

Excelsior Biopharma Inc. develops and sells pharmaceutical products in Taiwan, China, and internationally. It offers general pharmaceuticals; orphan drugs; antidotes; rapid test kits and reagent; consumer products under the Repavar, Om3gafort, Oral7, and Excelsior Probiotics brand names; and over the counter drugs under the Norit, Puresenna, and Tazac brand names. The company also provides specialty medicine and public health products. In addition, it is involved in importin…

Full company profile